MedTrace Logo

Brief Admission by Self-referral for Individuals With Self-harm: Effects on Compulsory Care

NCT06406972 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 7000

Last updated 2025-08-14

No results posted yet for this study

Summary

Brief Admission by self-referral (BA) is a standardized treatment model, providing patient-controlled and person-centered care. It was developed to reduce self-harm and compulsory care by promoting autonomy. Randomized clinical trials have not yielded significant between group differences with respect to inpatient care, including compulsory care. The major difficulty in evaluating BA is preventing the control group from cross-contamination, as in the implementation process of BA, all physicians, all inpatient and outpatient staff as well as managers need to be informed and undergo basic education regarding the intervention. As BA addresses a prevalent and frustrating issue in psychiatric health care, there is considerable risk that the approach leaks to the control group, reducing the possibility to detect between-group differences. In the current study this will be addressed through a register-based approach, comparing similar clinics, implementing BA at different timepoints over time. Individuals with traits of borderline personality disorder will be included and comparisons will be made with respect to compulsory care, voluntary inpatient care and mortality.

Conditions

  • Self-injury
  • Suicide
  • Suicide, Attempted
  • Self-harm
  • Borderline Personality Disorder
  • Emergency Psychiatric
  • Hospitalizations Psychiatric

Interventions

OTHER

Brief Admission by self-referral (BA)

Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.

Sponsors & Collaborators

  • Lund University

    collaborator OTHER

  • Linkoeping University

    collaborator OTHER_GOV

  • Region Skane

    lead OTHER

Principal Investigators

  • Sofie Sofie, PhD · Lund University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-15
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06406972 on ClinicalTrials.gov